Status:
ACTIVE_NOT_RECRUITING
Urine Alkalinisation in COVID-19
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborating Sponsors:
University of Pittsburgh
Conditions:
Covid19
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Since the outbreak of coronavirus disease 2019 (COVID-19), more than 100,000 patients have died in the United Kingdom. Acute kidney injury is common in critically ill patients with COVID-19. It is ass...
Detailed Description
Acute kidney injury (AKI) is common in patients with Coronavirus disease 2019 (COVID-19). Research has shown that the SARS-CoV-2 virus can directly infect kidney issue via the Angiotensin-converting-e...
Eligibility Criteria
Inclusion
- Confirmed Covid-19 positive
- Admission to Critical Care Unit
- Bladder catheter in situ
- Central line in place
- Age ≥18y
- Written informed consent to participate in the study
Exclusion
- Stage 3 AKI (as defined by Kidney Disease Improving Global Outcome criteria)
- Chronic kidney disease stage 4 or 5
- Contraindications to NaHCO3 therapy (e.g. risk of serious drug interaction, systemic metabolic alkalosis, congestive heart failure)
- Urine pH \> 7.5
- Serum sodium \>150mmol/L
- Blood pressure \>180/100mgHg
- Severe hypokalaemia (K\<3.0mmol/L)
- Severe hypocalcaemia (Cai \<0.8 mmol/L)
- Pregnant or lactating and breast-feeding women
- Patient is on a medication that may interact with sodium bicarbonate
Key Trial Info
Start Date :
October 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04806061
Start Date
October 15 2021
End Date
July 30 2024
Last Update
June 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's & St Thomas Foundation Hospital
London, United Kingdom, SE1 7EH
2
Guy's & St Thomas Hospital
London, United Kingdom, SE1 7EH